|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Essential Hypertension
|
|
0.010 |
GeneticVariation |
BEFREE |
This study examined the relationship between ANP Val7Met polymorphism (Single Nucleotide Polymorphism database ID: rs5063) and baseline blood pressure (BP), plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension.
|
16368448 |
2005 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Diastolic blood pressure
|
|
0.700 |
GeneticVariation |
GWASCAT |
A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure.
|
29455858 |
2018 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.010 |
GeneticVariation |
BEFREE |
The ANP rs5065 (2238T>C) C allele seems to exert a protective effect against CAD in T2D patients of African descent.
|
22170009 |
2012 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.010 |
GeneticVariation |
BEFREE |
Since gene variants are inherited randomly and not subject to confounding, we aimed to investigate whether the variant rs5068 within the NPPA locus is associated with incident type 2 diabetes.
|
24586593 |
2014 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Diabetes Mellitus
|
|
0.010 |
GeneticVariation |
BEFREE |
Carriers of rs5063 had lower NT-proANP levels (1427 versus 2291 pmol/L; P<0.001) and higher diastolic blood pressures (75 versus 73 mm Hg; P=0.009) and were at an increased risk of stroke when compared with wild-type subjects independent of age, sex, diabetes mellitus, hypertension, atrial fibrillation, and cholesterol levels (hazard ratio, 1.6; P=0.004).
|
25452597 |
2015 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Diabetes Mellitus
|
|
0.010 |
GeneticVariation |
BEFREE |
In Cox regression analysis adjusted for age, sex and BMI, we found that the carriers of at least one copy of the G allele of rs5068 had lower likelihood of incident diabetes within 14 years (HR = 0.88, 95% CI 0.78-0.99, p = 0.037).
|
24586593 |
2014 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Diabetes
|
|
0.010 |
GeneticVariation |
BEFREE |
In Cox regression analysis adjusted for age, sex and BMI, we found that the carriers of at least one copy of the G allele of rs5068 had lower likelihood of incident diabetes within 14 years (HR = 0.88, 95% CI 0.78-0.99, p = 0.037).
|
24586593 |
2014 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Coronary heart disease
|
|
0.020 |
GeneticVariation |
BEFREE |
Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease.
|
22575314 |
2012 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Coronary heart disease
|
|
0.020 |
GeneticVariation |
BEFREE |
Association between the atrial natriuretic peptide rs5065 gene polymorphism and the presence and severity of coronary artery disease in an Iranian population.
|
24487939 |
2014 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Coronary heart disease
|
|
0.010 |
GeneticVariation |
BEFREE |
Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia.
|
16721833 |
2006 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Coronary Artery Disease
|
|
0.030 |
GeneticVariation |
BEFREE |
The ANP rs5065 (2238T>C) C allele seems to exert a protective effect against CAD in T2D patients of African descent.
|
22170009 |
2012 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Coronary Artery Disease
|
|
0.030 |
GeneticVariation |
BEFREE |
The presence of the rs5065 ANP polymorphism is potentially associated with a reduced risk of CAD as well as with reduced severity of CAD independent of the general risk factors of CAD.
|
24487939 |
2014 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Coronary Artery Disease
|
|
0.030 |
GeneticVariation |
BEFREE |
The MA of rs5065 ANP gene variant associates with increased susceptibility to ACS and has unfavorable prognostic value in CAD.
|
22575314 |
2012 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia.
|
16721833 |
2006 |
|
rs5064
|
CLCN6;NPPA;NPPA-AS1
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
No association was found between the rs5064 (708C>T) single-nucleotide polymorphisms (SNPs) and pre-existing CAD or cardiovascular risk factors.
|
22170009 |
2012 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Coronary Arteriosclerosis
|
|
0.020 |
GeneticVariation |
BEFREE |
Association between the atrial natriuretic peptide rs5065 gene polymorphism and the presence and severity of coronary artery disease in an Iranian population.
|
24487939 |
2014 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Coronary Arteriosclerosis
|
|
0.020 |
GeneticVariation |
BEFREE |
Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease.
|
22575314 |
2012 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Coronary Arteriosclerosis
|
|
0.010 |
GeneticVariation |
BEFREE |
Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia.
|
16721833 |
2006 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Congestive heart failure
|
|
0.010 |
GeneticVariation |
BEFREE |
There was no significant association between genotypes of rs198389, rs5068, and rs198358 and heart failure risk.
|
23315043 |
2013 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Cerebrovascular accident
|
|
0.010 |
GeneticVariation |
BEFREE |
Carriers of rs5063 had lower NT-proANP levels (1427 versus 2291 pmol/L; P<0.001) and higher diastolic blood pressures (75 versus 73 mm Hg; P=0.009) and were at an increased risk of stroke when compared with wild-type subjects independent of age, sex, diabetes mellitus, hypertension, atrial fibrillation, and cholesterol levels (hazard ratio, 1.6; P=0.004).
|
25452597 |
2015 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Cerebrovascular accident
|
|
0.010 |
GeneticVariation |
BEFREE |
Two common single nucleotide polymorphisms (SNPs) in NPPA, rs5063 and rs5065, result in amino acid changes of the primary peptide and have been previously implicated in conditions associated with AF, including stroke and hypertension.
|
20543198 |
2010 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Cardiovascular Diseases
|
|
0.010 |
GeneticVariation |
BEFREE |
Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study.
|
24041948 |
2013 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Cardioembolic stroke
|
|
0.010 |
GeneticVariation |
BEFREE |
However, in logistic analysis for Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification of ischemic stroke, nonsynonymous rs5065 (STOP152Arg) and rs5067 in 3'UTR of NPPA, which were in complete linkage disequilibrium, showed significant associations with cardioembolic stroke.
|
22400494 |
2012 |
|
rs5067
|
CLCN6;NPPA;NPPA-AS1
|
Cardioembolic stroke
|
|
0.010 |
GeneticVariation |
BEFREE |
However, in logistic analysis for Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification of ischemic stroke, nonsynonymous rs5065 (STOP152Arg) and rs5067 in 3'UTR of NPPA, which were in complete linkage disequilibrium, showed significant associations with cardioembolic stroke.
|
22400494 |
2012 |
|
rs202102042
|
CLCN6;NPPA;NPPA-AS1
|
ATRIAL STANDSTILL 2
|
T |
0.800 |
CausalMutation |
CLINVAR |
|
|
|